DOCSLIB.ORG

2021 Winter Caregiver's Companion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2021 Winter Caregiver's Companion Winter 2021 Vol. 24 No.1 Fall 2020 Vol. 23 No. 3 Changes in Care Before and During COVID-19 COVID-19 vs. Influenza The Latest in Alzheimer's Research Our Mission: To provide educational programs, support services and assistance to caregivers, families and individuals with Alzheimer’s disease and other dementia. What's Inside: Support Groups - Pages 4 & 5 Page 7 Page 9 Caregiver's Corner Guest Article Changes in Our Loved One’s Care Before and During COVID Time for Your Flu Vaccine Page 10 Page 17 Research Corner From Your Editor The Latest in Research Parkinson’s Executive Director Administrative Manager Contact Information Kathleen Winters Alicia Vegerano Alzheimer’s Family Organization Board President Community Educators PO BOX 15489 Lori Wilson Brooksville FL 34604 The Villages & Marion County Board Vice President Jackie Kuhn-Damron Bill Tuttle Telephone: 352-616-0170 574-721-1177 Email: [email protected] Board Treasurer [email protected] Tyler Borowski www.alzheimersfamily.org Lake County & S. Sumter Board Secretary Jamilya Rahming Alexander Powell Vision Statement 352-396-2614 All those with Alzheimer’s or other forms of Board Members dementia, and their caregivers, will have a [email protected] Sharon Doncourt better quality of life. Ron Francis III Peg Pickett Ed Spinks The “Caregiver’s Companion” is published quarterly by Dr. Mary Stedman /AFO.FL The Alzheimer’s Family Organization. The Alzheimer’s Editor Family Organization disclaims any liability for damages resulting from articles, opinions, advertising, or Bill Tuttle AlzFamilyOrg representations expressed or implied in this publication. Design Any comments or claims are made solely by the individual author and do not necessarily represent the Jamilya Rahming views of any other Alzheimer’s Family Organization Contributing Authors Alzheimer’s Family Organization member or other persons, living or dead. Vicky Martinez All materials in this newsletter is offered as information to our readers. The Alzheimer’s Family Organization does James Finnigan not warrant, endorse, or recommend any provider, Ann Gayle program, or product. Jeff Pohlig The Alzheimer’s Family Organization conforms to the Florida “solicitations of Contributions Act” pertaining to charitable Dr. Lauren Dedea organizations: “A COPY OF THE OFFICIAL REGISTRATION AND FINANCIAL INFORMATION MAY BE OBTAINED FROM THE DIVISION OF CONSUMER SERVICES BY CALLING TOLL-FREE WITHIN THE STATE (1- 800-HELP FLA) REGISTRATION DOES NOT IMPLY ENDORSEMENT, APPROVAL, OR RECOMMENDATION BY THE STATE.” Winter 2021 Vol. 24 No. 1 Image Credits: Jackie Kuhn-Damron, Suzy Hazelwood, Geralt, Pexels, Pixabay 2 Alzheimer's Family Organization - Caregiver's Companion WORDS FROM THE EXECUTIVE DIRECTOR Happy New Year! Wow! It is 2021...it is hard to believe! I can’t say that I am sad to see 2020 be in the past. This year was a very trying time for all of us. All united under the same cloud of isolation, challenges, hardships, and fears. It is amazing that a virus that is so small it cannot be seen with the naked eye can bring an entire world to a halt. I am entering 2021 with hope and a vision for a better year for all. The AFO suffered tremendous financial hardship in 2020, but through the support of caregivers and the community at large, we are still here supplying services. The AFO was blessed to be covered in eleven newspaper articles and one television interview of our hardship and the community came through to support us. We look a bit different than we did, down to just four staff, our office closed, working out of our homes, providing support groups and educational events virtually, but we are here none the less! We are still offering our programs except for the Respite Care Financial Reimbursement Program as funds are not available currently. We will re-visit for 2022. The staff and I are slowly being able to be out more in the community, wearing our masks and supporting caregivers through home visits, meeting at outdoor space, or whatever is most comfortable for all parties involved. Our LEADER Task Force made strides in 2020 with meetings commencing via Zoom platform. Of the eight-county service area seven Sheriff’s Offices and one Police Dept. Were regulars at the meetings. A quick card was developed for deputies and officers, social workers and victim advocates. The Sheriff’s Summit plans are underway with the event being hopefully hosted in Hernando County this year and will be held on the first Friday in May as it has been in years past. The Task Force has recommended the Summit be rotated each year offering each county to host. Many of our support groups have continued via Zoom or conference call, and some have begun to meet face to face wearing masks and keeping with social distancing guidelines. Everyone has had to make concessions and accommodations due to Covid-19, but everyone is doing the best they can. With that said, we have decided to continue or educational series virtually until we see how the year progresses. We have all eleven months planned and the speakers confirmed. You can see the list in this issue of the Caregivers Companion. As this new year begins, all of us at the AFO wish you all the best, good health, safety and care. Please feel free to reach out to us at (352) 616-0170 or each of the Community Educators. Their contact information is: Jackie Kuhn-Damron at (574) 721-1177 or Jamilya Rahming at (352) 396-2614. The AFO stays committed to the needs of caregivers and the communities that we serve. We are only a phone call away. Peace to you. Respectfully, Kathleen M. Winters, Executive Director Alzheimer's Family Organization - Caregiver's Companion 3 AFO SUPPORT GROUPS People touched by Alzheimer’s disease and other related diseases come together in a confidential, safe environment to vent their frustrations, develop and share coping techniques, learn more about the disease and discover what resources are available to them. All support groups are facilitated by trained individuals. Due to COVID-19, please call the support group leader for more information. Timber Pines Country Club CITRUS Lake Port Square (Gated Community – must register with Sue to attend) Cornerstone Baptist Church (Must Call To Make Appointment) Lodge - Oak Room 1100 W. Highland Blvd, Inverness, FL 34452 600 Lake Port Blvd, Leesburg, FL 34748 6872 Timber Pines Blvd, Spring Hill, FL 34606 3rd Wednesday of the month at 1:30 PM Every Wednesday of the month at 1:30 PM 2nd Thursday of the month at 10:00 AM Leader: Debbie Selsavage 352-422-3663 Leader: Allison Church 352-728-8525, x232 Leader: Sue Simone 203-725-6888 Crystal River Library Lakeview Terrace 8619 Crystal St, Crystal River, FL 34428 HILLSBOROUGH 331 Raintree Dr, Altoona, FL 32702 2nd Thursday of the month at 1:30 PM 2nd Tuesday of the month at 1:30 PM Arden Courts of Tampa Leader: Cheryl Fletcher 352-409-5360 Leader: Debbie Selsavage 352-422-3663 (Please Call To Make Appointment) Lake Ridge Village Senior Helpers 14950 Casey Rd, Tampa, FL 33624 353 W Ardice Ave, Eustis, FL 32726 587 E Gulf To Lake Hwy, Lecanto, FL 34461 Frontal Temporal Degeneration & Alzheimer’s 3rd Thursday of the month at 3:00 PM 1st Friday of the month at 1:30 PM 2nd Sunday of the month at 1:00 PM Leader: Carolyn Costello 804-615-1117 Call Office for more information - 352-835-7191 Co-Leaders: Mary Anne Upham 813-786-8388 North Lake Presbyterian Church Doris Hogan 813-486-0554 HERNANDO 975 Rolling Acres Rd, Lady Lake, FL 32159 The Colonnade at Northdale Atria Evergreen Woods 1st Wednesday of the month at 1:00 PM 3401 W Bearss Ave, Tampa, FL 33618 Pool Clubhouse Leader: Louise Shuey 352-753-8262 2nd Tuesday of each month at 10:30 AM 7030 Evergreen Woods Trl, Spring Hill 34608 3rd Wednesday of the month at 1:00 PM Leader: Wenona Spencer 813-961-1044 2nd Tuesday of the month at 1:00 PM Co-Leaders: Louise Shuey 352-753-8262 2nd Saturday of the month at 4:00 PM LAKE Don Dati 352-259-5363 Leader: Lori Wilson 352-596-2055 Bridgewater at Waterman Village North Lake Presbyterian Church Bayfront Health Brooksville (Free Respite Care During Meeting) Early Stage Group (for early stage patients) Medical Arts Bldg. – Ste.120 500 Waterman Ave, Mt. Dora, FL 32757 Fellowship Center Room 2 17222 Hospital Blvd, Brooksville, FL 34601 3rd Wednesday of the month at 1:30 PM 975 Rolling Acres Rd, Lady Lake, FL 32159 2nd & 4th Monday of the month at 1:00 PM Co-Leaders: Coleen Connolly 352-383-0051, x313 1st and 3rd Friday of the month at 10:00 AM Co-Leaders: Donna Alford 813-469-5024 Chaplain Robert Nickell 352-383-0051, x229 Leader: Louise Shuey 352-753-8262 Bill Tuttle 813-712-9058 Madison at Clermont Osprey Lodge Assisted Living & Memory Care Bible Baptist Church 650 E. Minnehaha Ave, Clermont, FL 34711 (Free Respite Care During Meeting) 15901 Little Ranch Rd, Spring Hill, FL 34610 1st Wednesday of the month at 4:00 PM 1761 Nightingale Ln, Tavares, FL 32778 2nd Tuesday of the month at 9:00 AM Co-Leaders: Paul Clews 352-241-0844 3rd Tuesday of the month Leader: Sandy Locke 727-856-6815 Ashley Alvarez Alzheimer’s Café: 11:30 AM - 12:30PM East Hernando Library Chapel of Christian Faith Support Group: 12:30 PM - 1:30 PM 6457 Windmere Rd., Brooksville, FL 34602 1401 Paradise Drive, Lady Lake, FL 32159 Leader: Ruth Cantillon 352-253-5100 2nd Tuesday of the month at 11:00 AM 3rd Thursday of the month at 10:00 AM Leader: Glorea Charland 352-754-4043 MARION Leader: Martha Hyatt 352-748-7633 Forest Oaks of Spring Hill Brookdale Canopy Oaks (Please RSVP) Clermont Arts & Recreation Center 8055 Forest Oaks Blvd, Spring Hill, FL 34606 9070 SW 80th Ave, Ocala, FL 34481 Virtual Group 1st Wednesday of the month at 11:00 AM 2nd & 4th Thursday of the month at 2:00 PM 1st Monday of the month at 4:00 PM Co-Leaders: Leigh Dingle 352-683-3323 Leader: Mikaela Saunderson 813-860-4282 Co-Leaders: Courtney Schmidt.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7,786,126 B2 Mccreary Et Al
    USOO7786126B2 (12) United States Patent (10) Patent No.: US 7,786,126 B2 McCreary et al. (45) Date of Patent: Aug. 31, 2010 (54) COMBINATION PREPARATIONS OTHER PUBLICATIONS COMPRISING SLV3O8 AND A DOPAMINE AGONST Salvati et al. NW-1048 is a novel, reversible and selective MAO-B (75) Inventors: Andrew C. McCreary, Weesp (NL); inhibitor with neuroprotective effects in a model of Parkinson's dis Gustaaf J. M. Van Scharrenburg, ease. Society for Neuroscience Abstract, 2000 vol. 26, No. 1-2, pp. Weesp (NL); Martinus Th. M. Tulp, abstract No. 765.11. Weesp (NL) (Continued) (73) Assignee: Solvay Pharmaceuticals B.V., Weesp Primary Examiner Jennifer M Kim (NL) (74) Attorney, Agent, or Firm—Finnegan, Henderson, (*) Notice: Subject to any disclaimer, the term of this Farabow, Garrett & Dunner, L.L.P. patent is extended or adjusted under 35 U.S.C. 154(b) by 347 days. (57) ABSTRACT (21) Appl. No.: 11/762,206 A composition containing SLV308 or its N-oxide, or at least (22) Filed: Jun. 13, 2007 one pharmacologically acceptable salt thereof: (65) Prior Publication Data SLV308 US 2007/O293505 A1 Dec. 20, 2007 O Related U.S. Application Data 1. (60) Provisional application No. 60/814,051, filed on Jun. 16, 2006. (51) Int. Cl. (S-O-V / " A63/497 (2006.01) SLV308 N-oxide A 6LX 3L/95 (2006.01) A6 IK3I/35 (2006.01) (52) U.S. Cl. ................... 514/254.02:514/567; 514/649 HN -l O (58) Field of Classification Search ............ 5147254.02 514/567, 649 / V CH See application file for complete search history.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Nitecapone Item No. 18656 CAS Registry No.: 116313-94-1 Formal Name: 3-[(3,4-dihydroxy-5-nitrophenyl) methylene]-2,4-pentanedione O Synonym: OR-462 O2N MF: C12H11NO6 FW: 265.2 Purity: ≥98% HO O UV/Vis.: λmax: 225, 301 nm Supplied as: A crystalline solid OH Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Nitecapone is supplied as a crystalline solid. A stock solution may be made by dissolving the nitecapone in the solvent of choice. Nitecapone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of nitecapone in ethanol is approximately 5 mg/ml and approximately 30 mg/ml in DMSO and DMF. Nitecapone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, nitecapone should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Nitecapone has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Nitecapone is a reversible inhibitor of S-catechol-O-methyltransferase (S-COMT; IC50 = 300 nM in rat liver).1 It is selective for S-COMT over tyrosine hydroxylase, dopamine-β-hydroxylase, DOPA decarboxylase, monoamine oxidase A (MAO-A), and MAO-B (IC50s = >1 µM for all). In vivo, nitecapone inhibits liver, duodenal, and brain S-COMT (ID50s = 5, 5, and 25 mg/kg, respectively).
    [Show full text]
  • Case 2:10-Cv-05078-CCC-MF Document 540 Filed 09/20/13 Page 1 of 59 Pageid: 14610
    Case 2:10-cv-05078-CCC-MF Document 540 Filed 09/20/13 Page 1 of 59 PageID: 14610 NOT FOR PUBLICATION UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY TEA NEUROSCIENCE, INC., TEVA PHARMACEUTICALS USA INC.. and TEVA PHARI’IACEUTICALS INDUSTRIES, LTD., Civil Action No. 2:lO-cv-05078 Plaintiffs, V. Opinion WATSON LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., MYLAN INC., ORCHID CHEMICALS & PHARMACEUTICALS LTD., ORCHID HEALTHCARE (a division of Orchid Chemicals & Pharmaceuticals Ltd.) and ORGENUS PHARMA INC. Defendants. TEVA NEUROSCIENCE, INC., TEVA PHARMACEUTICALS USA, INC., and TEVA PHARMACEUTICALS INDUSTRIES, LTD., Civil Action No. 2:1l-cv-3076 Plaintiffs, v. APOTEX CORP. and APOTEX INC. Defendants. Case 2:10-cv-05078-CCC-MF Document 540 Filed 09/20/13 Page 2 of 59 PageID: 14611 Claire C. Cecchi, U.S.D.J. This matter comes before the Court by complaint of Teva Neuroscience, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. (collectively, “Teva”) against Mylan’ and certain other defendants,2 This case concerns the validity of United States Patent No. 5,453,446 (“the ‘446 Patent”), which is directed to a method of treating Parkinson’s disease, This Court conducted a non-jury trial in this matter from May 15-31, 2013. This Opinion constitutes the Court’s findings of fact and conclusions of law pursuant to Federal Rule of Civil Procedure 52(a). For the reasons stated herein, a finding in favor of Teva will be entered. BACKGROUND I. The Parties Plaintiff Teva Pharmaceutical Industries Ltd. (“Teva Ltd.”) is an Israeli company with its principal place of business at 5 Basel Street, Petach Ti.Kva, 49131, Israel.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Development of Purification Strategies for SCOMT and MBCOMT Proteins by Affinity Chromatography
    UNIVERSIDADE DA BEIRA INTERIOR Ciências Development of purification strategies for SCOMT and MBCOMT proteins by affinity chromatography Carla Sofia Ferreira Pereira Dissertação para obtenção do Grau de Mestre em Bioquímica (2º ciclo de estudos) Orientador: Prof. Doutor Luís António Paulino Passarinha Coorientadora: Prof. Doutora Ângela Maria Almeida de Sousa Covilhã, Outubro de 2016 Development of purification strategies for SCOMT and MBCOMT proteins and affinity chromatography Folha em branco ii Development of purification strategies for SCOMT and MBCOMT proteins and affinity chromatography Acknowledgments Firstly, I would like to express my sincere gratitude to my advisors Professor Luís Passarinha and Professora Ângela Sousa by excellent monitoring and immense knowledge scientific. I have no words for the confidence placed in me and in my work. Thank you for motivation to never give up my objectives. I must mention that it was for me a real privilege to work beside you. To my dear family, parents and sister, that I love very much, want to thank all the support, unconditional love but also for patience in difficult times and to be present at all times of my life. I would also like to express my gratitude to Margarida Grilo and Fátima Santos, whose expertise, advice and encouragement made my work much more easy. I specially thank my lab colleagues for the unconditional help, friendship and support, and all the fun we had along this journey. I would like to thank the Universidade da Beira Interior and Centro de Investigação em Ciências da Saúde for allowing the development of my research work. Last but not the least, I would like to thank all my friends, particulary, Cláudia Faria and Leonor Varandas for the encouragement all this time and for helping me make me the person I am today, thank all friendship.
    [Show full text]
  • Lyophilization and a Preliminary Thermodynamic Characterization of Recombinant SCOMT His6
    UNIVERSIDADE DA BEIRA INTERIOR Ciências Lyophilization and a preliminary thermodynamic characterization of recombinant SCOMT_His6 Rúben Miguel Oliveira Coval Dissertação para obtenção do Grau de Mestre em Biotecnologia (2º ciclo de estudos) Orientador: Professor Doutor Luís António Paulino Passarinha Co-orientador: Mestre Augusto Quaresma Henriques Pedro Covilhã, outubro de 2015 ii “When we are no longer able to change a situation, we are challenged to change ourselves” Viktor Frankl iii iv Acknowledgments First off all, I would like to express my sincere gratitude to my parents, brother and girlfriend for all their sacrifices, encouragement, support and unconditional love. Furthermore, I would also like to give a special thanks to my supervisors Professor Doctor Luís Passarinha and Master Augusto Pedro for all their availability, guidance, expertise, patience and trust. Their help, efforts, vast knowledge, criticism and suggestions were crucial for the development of this project. It was a privilege to work and learn with them. I would also like to acknowledge the University of Beira Interior, in particular the Health Sciences Research Center, where all the work was developed. I am also grateful to all people involved in the Health Sciences Research Center of the University of Beira Interior, particularly to my colleagues in the Biotechnology and Biomolecular Sciences group whose advice and companionship made my work much more easy and pleasant. I could not fail to name a few people who were crucial in this process. I want to make a special thanks to Margarida Grilo and Guilherme Espírito Santo throughout the laboratory help and especially for all past knowledge that were the basis of all this work, and to Filipe Frias for the companionship and help.
    [Show full text]
  • Catechol-O-Methyltransferase Inhibitor, on the Motor Response to Acute Treatment with Levodopa in Patients with Parkinson's Disease
    18616ournal ofNeurology, Neurosurgery, and Psychiatry 1994;57:186-189 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.57.2.186 on 1 February 1994. Downloaded from Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease Marcelo Merello, Andrew J Lees, Roy Webster, Michael Bovingdon, Ariel Gordin Abstract treatment.7-'0 The oral bioavailability of lev- Catechol-O-methyltransferase (COMT) odopa is low due to first pass metabolism inhibitors may be useful in the treatment which is at least partly due to the high activity of Parkinson's disease by improving the of COMT in the gut and liver." 12 The com- bioavailability of levodopa and by pro- bination of a peripheral COMT inhibitor longing its effects. Entacapone (OR-611), with levodopa/DCI therapy might therefore a novel COMT inhibitor, which does not produce a smoother and more prolonged cross the blood brain barrier, was motor response in patients with Parkinson's assessed in 12 patients with Parkinson's disease."3 14 As early as in 1971 Ericsson'5 disease and motor fluctuations in a reported beneficial effects with a COMT randomised, double-blind, cross-over, inhibitor with concomitant reduction in single dose study. The magnitude and levodopa-induced dyskinesias. More recently, duration of the therapeutic response to a a new generation of COMT inhibitors have single dose of 200 mg levodopa/50 mg been developed, which are much more potent carbidopa was evaluated after concomi- and specific."'3 1620 Fluorodopa positron tant placebo, or 200 or 800 mg enta- emission tomography (PET) studies in mon- capone.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (Boosters)—Escort for Drugs Against Degrading Enzymes and Beyond
    Scientia Pharmaceutica Review Pharmacokinetic Enhancers (Boosters)—Escort for Drugs against Degrading Enzymes and Beyond Jürgen Krauß and Franz Bracher * Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians University, Butenandtstr. 5-13, 81377 Munich, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-89-218077301 Received: 22 August 2018; Accepted: 20 September 2018; Published: 27 September 2018 Abstract: Pharmacokinetic enhancers (boosters) are compounds used in combination with a primary therapeutic agent (drug) and are not used for their direct effects on the disease but because they enhance or restore the activity of the primary agent. Hence, in certain cases, they represent an indispensable escort for enzyme-labile drugs. Pharmacokinetic enhancers can exert their activity on different ways. In the most common case, they inhibit enzymes such as human cytochrome P450 enzymes in the liver or other organs and, thereby, block or reduce undesired metabolism and inactivation of the primary drug. In this review, an overview will be given on the therapeutically most important classes of pharmacokinetic enhancers like β-lactamase inhibitors, inhibitors of CYP (cytochrome P450) enzymes in HIV therapy and hepatitis C, boosters for fluoropyrimidine-type anticancer agents, compounds utilized for enabling therapy of Parkinson’s disease with levodopa, and others. Inhibitors of efflux pumps in both pathogenic bacteria and tumor cells will be addresses shortly. Keywords: pharmacokinetic enhancer; booster; enzyme; inhibitor; β-lactamase; DOPA decarboxylase; antibiotic; resistance; efflux pump; protease; antimetabolite 1. Introduction Pharmacokinetic enhancers, which are also named boosters or boosting agents, are compounds used in combination with a primary therapeutic agent (drug) not for their direct effects on the disease itself but because they enhance or restore the activity, increase the levels, and/or prolong the half-life of the primary agent.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (Boosters)—Escort for Drugs Against Degrading Enzymes and Beyond
    Review Pharmacokinetic Enhancers (Boosters)—Escort for Drugs against Degrading Enzymes and Beyond Jürgen Krauß and Franz Bracher * Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians University, Butenandtstr. 5-13, 81377 Munich, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-89-218077301 Received: 22 August 2018; Accepted: 20 September 2018; Published: 27 September 2018 Abstract: Pharmacokinetic enhancers (boosters) are compounds used in combination with a primary therapeutic agent (drug) and are not used for their direct effects on the disease but because they enhance or restore the activity of the primary agent. Hence, in certain cases, they represent an indispensable escort for enzyme-labile drugs. Pharmacokinetic enhancers can exert their activity on different ways. In the most common case, they inhibit enzymes such as human cytochrome P450 enzymes in the liver or other organs and, thereby, block or reduce undesired metabolism and inactivation of the primary drug. In this review, an overview will be given on the therapeutically most important classes of pharmacokinetic enhancers like β-lactamase inhibitors, inhibitors of CYP (cytochrome P450) enzymes in HIV therapy and hepatitis C, boosters for fluoropyrimidine-type anticancer agents, compounds utilized for enabling therapy of Parkinson’s disease with levodopa, and others. Inhibitors of efflux pumps in both pathogenic bacteria and tumor cells will be addresses shortly. Keywords: pharmacokinetic enhancer; booster; enzyme; inhibitor; β-lactamase; DOPA decarboxylase; antibiotic; resistance; efflux pump; protease; antimetabolite 1. Introduction Pharmacokinetic enhancers, which are also named boosters or boosting agents, are compounds used in combination with a primary therapeutic agent (drug) not for their direct effects on the disease itself but because they enhance or restore the activity, increase the levels, and/or prolong the half-life of the primary agent.
    [Show full text]
  • Development of a PC12 Cell-Based Assay for in Vitro Screening of Catechol-O- Methyltransferase Inhibitors
    bioRxiv preprint doi: https://doi.org/10.1101/694596; this version posted July 7, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Development of a PC12 cell-based assay for in vitro screening of catechol-O- methyltransferase inhibitors Gongliang Zhang1 , Ingrid P. Buchler1, Michael DePasquale1, Michael Wormald1,2, Gangling Liao1, Huijun Wei1,2, James C. Barrow1,2, and Gregory V. Carr1,2 1 Lieber Institute for Brain Development, Baltimore, MD 21205 2 Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21205 * For correspondence Gregory V. Carr, PhD Investigator, Lieber Institute for Brain Development Assistant Professor of Pharmacology and Molecular Sciences Johns Hopkins University School of Medicine 855 North Wolfe Street, Room 373 Baltimore, MD 21205 443-287-4073 [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/694596; this version posted July 7, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT The male rat adrenal pheochromocytoma cell-originated PC12 cell line can synthesize and release catecholamine neurotransmitters, and it has been widely used as a model system in cell biology and toxicology research. Catechol-O-methyltransferase (COMT) is involved in the inactivation of the catecholamine neurotransmitters, and it is particularly important for theregulation of dopamine. In this study, we explored the feasibility of using PC12 cells as an in vitro drug screening platform to compare the activity of multiple COMT inhibitors.
    [Show full text]